GLP-1 RA on Liver OMICS in MASLD

Participation Deadline: 12/01/2028
Apply Now

Description

The study involves patients with a diagnosis of MASLD by histology and have diabetes/obesity. The ‘omics’ ( lipidomics, proteomics, metabolites, and inflammatory profiles and transcriptomics) data of liver tissue and plasma of patients will be compared between patients who have received 1 year of GLP-1 treatment with those who did not have GLP-1 agents.

The study will evaluate the changes in different ‘omics’ and metabolites in the liver tissue following the use of GLP-1 agents in these patients